In line Q1 and on track deleveraging; worth a go
15/05/24 -"The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand yoy and the deleveraging initiatives remained on ..."
Pages
53
Language
English
Published on
15/05/24
You may also be interested by these reports :
24/06/26
Rather than trying to figure out who will win the obesity race, why not bet on more defensive upstream API production?
23/06/26
Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is ...
19/06/26
Evaluating Pharma’s Defences
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...